Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Psyence BiomedicalPBM +3.95%14 EV-to-FCF is -1.55 as of Jul. 29, 2026. GuruFocus rates PBM with a GF Score™ of 14/100. The stock has 4 warning signs investors should review. Among 344 Biotechnology companies, Psyence Biomedical ranks worse than 290697.38% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Psyence Biomedical's Enterprise Value is $12.62 Mil.
Psyence Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.14 Mil. Therefore, Psyence Biomedical's EV-to-FCF for today is -1.55.
The historical rank and industry rank for Psyence Biomedical's EV-to-FCF or its related term are showing as below:
PBM'
s EV-to-FCF Range Over the Past 10 Years
Min: -1.55 Med: 0 Max: 0
Current: -1.55
PBM's EV-to-FCF is ranked worse than 100% of 344
companies
in the Biotechnology industry
Industry Median: 14.835
vs PBM: -1.55
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Psyence Biomedical's PE Ratio (TTM) for today is calculated as:
Psyence Biomedical's share price for today is $3.16.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Psyence Biomedical's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was $-12.560.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Psyence Biomedical EV-to-FCF Related Terms
Psyence Biomedical EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Psyence Biomedical's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Psyence Biomedical's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Psyence Biomedical EV-to-FCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Psyence Biomedical's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Psyence Biomedical's EV-to-FCF falls into.
Psyence Biomedical's current Enterprise Value is $12.62 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Psyence Biomedical's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $-8.14 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Psyence Biomedical (PBM) has a EV-to-FCF of -1.55 as of Jul. 29, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Psyence Biomedical and its competitors. According to the industry distribution chart, Psyence Biomedical ranks #999999 out of 344 companies in the Biotechnology industry.
Is Psyence Biomedical's EV-to-FCF too high?
Psyence Biomedical's current EV-to-FCF is -1.55. Based on the distribution chart, Psyence Biomedical ranks #999999 out of 344 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Psyence Biomedical has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Psyence Biomedical's EV-to-FCF compare to KPRX and AEON?
According to the Biotechnology industry distribution chart, Psyence Biomedical ranks #999999 out of 344 companies for EV-to-FCF. This places Psyence Biomedical in the lower half of its industry. The industry median EV-to-FCF is 14.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.84, based on 344 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Psyence Biomedical and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Psyence Biomedical's current EV-to-FCF is -1.55. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Psyence Biomedical stock overvalued right now?
Psyence Biomedical (PBM) has a current EV-to-FCF of -1.55. The current EV-to-FCF is -1.55. Psyence Biomedical's overall GF Score™ is 14/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Psyence Biomedical (PBM), the current EV-to-FCF is -1.55 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing. It develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The company has commenced the clinical trial process to evaluate the safety and efficacy of its product candidates. It cultivates natural psilocybin mushrooms at its federally licensed facility in Southern Africa. This product is produced for export to its partners across the world to be processed into a standardized encapsulated product.
14GF Score
Get the complete analysis for PBM
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PBM has been successfully added to your 
